Generic and biosimilar medicines provider Sandoz, part of Swiss pharmaceutical company Novartis Pharma AG (SIX:NOVN) (NYSE:NVS), said on Friday that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn).
Dveloped by Polpharma Biologics, Tyruko is approved to treat all indications covered by the reference medicine Tysabri (natalizumab), offering a new option for managing relapsing forms of multiple sclerosis (MS) and Crohn's disease in adults.
It is the first and only FDA-approved biosimilar for relapsing forms of MS.
The FDA's approval was based on clinical studies which demonstrated Tyruko's parallel efficacy, safety and immunogenicity to the reference medicine.
Sandoz's collaboration with Polpharma Biologics, initiated in 2019, enables Tyruko's global commercialisation while Polpharma retains responsibility for its development and manufacturing. Sandoz holds the worldwide rights for distribution.
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical
Veeda Group rebrands as 'Veeda Lifesciences'
ANI Pharmaceuticals launches generic Motegrity tablets
Hikma Pharmaceuticals USA receives FDA approval for diabetes drug
Full Circles Therapeutics advances non-viral gene editing innovation